Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amedisys Inc (NQ: AMED )

95.96 +0.57 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,700
Open 95.19
Bid (Size) 94.68 (1)
Ask (Size) 99.90 (2)
Prev. Close 95.39
Today's Range 95.17 - 95.97
52wk Range 89.55 - 98.95
Shares Outstanding 32,631,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination, Support for Caregivers 
From Amedisys, Inc.
Via GlobeNewswire
AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q2 2024
AMED stock results show that Amedisys beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+1.04%
+1.04%
1 Month
+0.15%
+0.15%
3 Month
-2.06%
-2.06%
6 Month
+3.90%
+3.90%
1 Year
+4.03%
+4.03%

More News

Read More
AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
Via InvestorPlace
Is NASDAQ:AMED suited for quality investing?
Via Chartmill
What 11 Analyst Ratings Have To Say About Amedisys
Via Benzinga
Analyst Ratings for Amedisys
Via Benzinga
3 Stocks To Turn $1,000 Into $10,000 in 10 Years
Via InvestorPlace
3 Stocks Profiting from America’s Long-Term Care Crisis
Via InvestorPlace
Cantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To Know
Via Benzinga
The 3 Best Stock Picks for This Week
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
Expert Ratings for Amedisys
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Is UnitedHealth Group Stock a Buy Now?
Via The Motley Fool
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023
Via Benzinga
AMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amedisys, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
Via Benzinga
Optum's Decision To Target Amedisys Is Intriguing, Says Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.